Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin

Novartis' Sandoz loses bid to break United Therapeutics' exclusive device deal for Remodulin

Source: 
Fierce Pharma
snippet: 

Branded drugmakers often take creative strategies to protect their meds from generic competition. In United Therapeutics' case, the lever for shielding Remodulin was an exclusive deal with a drug-pump maker, or so Novartis' Sandoz contended. But a judge didn't buy that argument.